Glucotrack, Inc. (GCTK) stock
GCTKOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$0.68−0.04 (-5.56%)
Close on Oct 19, 2026Market cap $3.43MP/E 0.0Yield –
Glucotrack r&d expenses
Research and development expenses are spending on new products and technology.
Glucotrack's R&D Expenses for the twelve months ending Jun 30, 2026 was $8.94M, up 1.8% year over year. For fiscal 2025 it was $9.81M, up 3.3% from the year before. Over ten years it grew 15.8% a year on average. The highest annual figure on record is $9.81M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.81M | +3.3% |
| FY2024 | Dec 31, 2024 | $9.50M | +101.9% |
| FY2023 | Dec 31, 2023 | $4.70M | +139.1% |
| FY2022 | Dec 31, 2022 | $1.97M | +8.7% |
| FY2021 | Dec 31, 2021 | $1.81M | +18.1% |
| FY2020 | Dec 31, 2020 | $1.53M | -4.6% |
| FY2019 | Dec 31, 2019 | $1.61M | -47.0% |
| FY2018 | Dec 31, 2018 | $3.03M | -5.4% |
| FY2017 | Dec 31, 2017 | $3.21M | +11.3% |
| FY2016 | Dec 31, 2016 | $2.88M | +27.0% |
| FY2015 | Dec 31, 2015 | $2.27M | +22.6% |
| FY2014 | Dec 31, 2014 | $1.85M | -6.9% |
| FY2013 | Dec 31, 2013 | $1.99M | +3.4% |
| FY2012 | Dec 31, 2012 | $1.92M | +7.3% |
| FY2011 | Dec 31, 2011 | $1.79M | +91.6% |
| FY2010 | Dec 31, 2010 | $934.06K | -7.1% |
| FY2009 | Dec 31, 2009 | $1.01M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.02M | -36.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.13M | +13.9% |
| Q4 FY2025 | Dec 31, 2025 | $1.63M | -4.2% |
| Q3 FY2025 | Sep 30, 2025 | $3.17M | +53.4% |
| Q2 FY2025 | Jun 30, 2025 | $3.15M | -12.2% |
| Q1 FY2025 | Mar 31, 2025 | $1.87M | -12.9% |
| Q4 FY2024 | Dec 31, 2024 | $1.70M | -2.5% |
| Q3 FY2024 | Sep 30, 2024 | $2.06M | +21.9% |
| Q2 FY2024 | Jun 30, 2024 | $3.59M | +472.4% |
| Q1 FY2024 | Mar 31, 2024 | $2.15M | +234.6% |
| Q4 FY2023 | Dec 31, 2023 | $1.74M | +188.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.69M | +290.1% |
| Q2 FY2023 | Jun 30, 2023 | $627.00K | +33.7% |
| Q1 FY2023 | Mar 31, 2023 | $642.00K | +39.6% |
| Q4 FY2022 | Dec 31, 2022 | $604.00K | -17.6% |
| Q3 FY2022 | Sep 30, 2022 | $434.00K | -2.9% |
| Q2 FY2022 | Jun 30, 2022 | $469.00K | +46.1% |
| Q1 FY2022 | Mar 31, 2022 | $460.00K | +48.9% |
| Q4 FY2021 | Dec 31, 2021 | $733.00K | +177.7% |
| Q3 FY2021 | Sep 30, 2021 | $447.00K | -6.1% |
| Q2 FY2021 | Jun 30, 2021 | $321.00K | -15.3% |
| Q1 FY2021 | Mar 31, 2021 | $309.00K | -25.2% |
| Q4 FY2020 | Dec 31, 2020 | $264.00K | -34.4% |
| Q3 FY2020 | Sep 30, 2020 | $476.00K | +26.1% |
| Q2 FY2020 | Jun 30, 2020 | $379.00K | -5.5% |
| Q1 FY2020 | Mar 31, 2020 | $413.00K | -2.9% |
| Q4 FY2019 | Dec 31, 2019 | $402.38K | -66.9% |
| Q3 FY2019 | Sep 30, 2019 | $377.38K | -29.3% |
| Q2 FY2019 | Jun 30, 2019 | $401.12K | -42.0% |
| Q1 FY2019 | Mar 31, 2019 | $425.12K | -28.3% |
| Q4 FY2018 | Dec 31, 2018 | $1.21M | -11.6% |
| Q3 FY2018 | Sep 30, 2018 | $534.13K | -15.9% |
| Q2 FY2018 | Jun 30, 2018 | $691.89K | +12.2% |
| Q1 FY2018 | Mar 31, 2018 | $592.70K | +1.9% |
| Q4 FY2017 | Dec 31, 2017 | $1.37M | +109.7% |
| Q3 FY2017 | Sep 30, 2017 | $635.48K | -8.6% |
| Q2 FY2017 | Jun 30, 2017 | $616.82K | – |
| Q1 FY2017 | Mar 31, 2017 | $581.54K | – |
| Q4 FY2016 | Dec 31, 2016 | $654.98K | – |
| Q3 FY2016 | Sep 30, 2016 | $695.44K | – |
See a number that looks wrong?